{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:53:22Z","timestamp":1787226802294,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s13555-024-01122-2","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:15:05Z","timestamp":1709817305000},"page":"729-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety of Secukinumab from 1\u00a0Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials"],"prefix":"10.1007","volume":"14","author":[{"given":"Rui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh Kumar","family":"Gurusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl","family":"Mendelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"1122_CR1","unstructured":"Secukinumab Summary of Product Characteristics (SmPC). Basel: Novartis Pharma AG."},{"key":"1122_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, et\u00a0al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401:747\u201361.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"1122_CR3","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, et\u00a0al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21-s40.","journal-title":"Clin Microbiol Infect"},{"key":"1122_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12016-021-08879-w","volume":"62","author":"JL Waldron","year":"2022","unstructured":"Waldron JL, Schworer SA, Kwan M. Hypersensitivity and immune-related adverse events in biologic therapy. Clin Rev Allergy Immunol. 2022;62:413\u201331.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1122_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et\u00a0al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"1122_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaad.2017.04.1133","volume":"77","author":"MJM Rodr\u00edguez-Z\u00fa\u00f1iga","year":"2017","unstructured":"Rodr\u00edguez-Z\u00fa\u00f1iga MJM, Garc\u00eda-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77:657-66.e8.","journal-title":"J Am Acad Dermatol"},{"key":"1122_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/1744666X.2020.1740593","volume":"16","author":"F Caso","year":"2020","unstructured":"Caso F, Chimenti MS, Navarini L, Ruscitti P, Peluso R, Girolimetto N, et\u00a0al. Metabolic syndrome and psoriatic arthritis: considerations for the clinician. Expert Rev Clin Immunol. 2020;16:409\u201320.","journal-title":"Expert Rev Clin Immunol"},{"key":"1122_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/ijd.15910","volume":"61","author":"D Mintoff","year":"2022","unstructured":"Mintoff D, Benhadou F, Pace NP, Frew JW. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61:1175\u201386.","journal-title":"Int J Dermatol"},{"key":"1122_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bjd.20136","volume":"185","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, et\u00a0al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021;185:935\u201344.","journal-title":"Br J Dermatol"},{"key":"1122_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski BE, Baddley JW, Deodhar AA, Magrey M, Rich PA, Soriano ER, et\u00a0al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157:43\u201351.","journal-title":"JAMA Dermatol"},{"key":"1122_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et\u00a0al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1122_CR12","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et\u00a0al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102: adv00698.","journal-title":"Acta Derm Venereol."},{"key":"1122_CR13","doi-asserted-by":"crossref","unstructured":"Sticherling M, Nikkels AF, Hamza AM, Kwong P, Szepietowski JC, El Sayed M et\u00a0al. Secukinumab in pediatric patients with plaque psoriasis: pooled safety analysis from two phase 3 randomized clinical trials. Am J Clin Dermatol. 2023.","DOI":"10.1007\/s40257-023-00782-8"},{"key":"1122_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/ard-2022-222849","volume":"82","author":"HI Brunner","year":"2023","unstructured":"Brunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, et\u00a0al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82:154\u201360.","journal-title":"Ann Rheum Dis"},{"key":"1122_CR15","unstructured":"International Conference on Harmonization. Periodic benefit-risk evaluation report (PBRER) E2C(R2). 2012. https:\/\/database.ich.org\/sites\/default\/files\/E2C_R2_Guideline.pdf. Accessed 1 Aug 2023."},{"key":"1122_CR16","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"1122_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","volume":"47","author":"HA Sampson","year":"2006","unstructured":"Sampson HA, Mu\u00f1oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et\u00a0al. Second symposium on the definition and management of anaphylaxis: summary report\u2013second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 2006;47:373\u201380.","journal-title":"Ann Emerg Med"},{"key":"1122_CR18","unstructured":"Mortality Analyses. https:\/\/coronavirus.jhu.edu\/data\/mortality2023."},{"key":"1122_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.992713","volume":"13","author":"A Vassilopoulos","year":"2022","unstructured":"Vassilopoulos A, Shehadeh F, Benitez G, Kalligeros M, Cunha JS, Cunha CB, et\u00a0al. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 992713.","journal-title":"Front Pharmacol"},{"key":"1122_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","volume":"23","author":"H Eppinga","year":"2017","unstructured":"Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij V, van der Woude CJ, et\u00a0al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1783\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1122_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/rheumatology\/keaa062","volume":"59","author":"B Pittam","year":"2020","unstructured":"Pittam B, Gupta S, Harrison NL, Robertson S, Hughes DM, Zhao SS. Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2020;59:2199\u2013206.","journal-title":"Rheumatology (Oxford)"},{"key":"1122_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"1122_CR23","unstructured":"Howard J. Minimum latency & types or categories of cancer. 2014."},{"key":"1122_CR24","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et\u00a0al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020;59:3834\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"1122_CR25","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1993","volume":"102","author":"K Reich","year":"2022","unstructured":"Reich K, Tha\u00e7i D, Stingl G, Andersen JS, Hiort LC, Lexner MO, et\u00a0al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. Acta Derm Venereol. 2022;102: adv00683.","journal-title":"Acta Derm Venereol."},{"key":"1122_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","volume":"86","author":"MJ Murphy","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86:1080\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"1122_CR27","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jamaoncol.2022.4919","volume":"8","author":"MV Ragavan","year":"2022","unstructured":"Ragavan MV, Legaspi N, LaLanne A, Hong JC, Small EJ, Borno HT. Analysis of serious adverse event reporting for patients enrolled in cancer clinical trials during the COVID-19 pandemic. JAMA Oncol. 2022;8:1849\u201351.","journal-title":"JAMA Oncol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01122-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T12:18:52Z","timestamp":1711455532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01122-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01122-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark Lebwohl is an employee of Mount Sinai and receives research funds from Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc., and is a consultant for Almirall, AltruBio Inc., Anaptys Bio, Apogee, Arcutis, Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, EPI, Evommune, Inc., Facilitation of International Dermatology Education, Forte biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Alice B Gottlieb has received research\/educational grants from Anaptyps Bio, Highlights Therapeutics, Moonlake Immunotherapeutics AG, Janssen, Novartis, Bristol Myers Squibb, and UCB Pharma, (all paid to Mount Sinai School of Medicine); has received honoraria as an advisory board member and consultant for Amgen, Anaptyps Bio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Eli Lilly, Highlights Therapeutics, Janssen, Novartis, Sanofi, UCB, and Xbiotech. Philip J Mease has received grant\/research support from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer and UCB; is a consultant for: AbbVie, Amgen, BMS, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB; Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Crescendo Bioscience, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer, and UCB. Atul Deodhar has received honoraria for consulting or speaking for, or has received research grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Venkatesh Kumar Gurusamy is employee of Novartis. Rui Sun, Mercedes Bustamante, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, and Victor Dong are employees and own shares of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All AEs were assessed in accordance with Good Pharmacovigilance Practice Module VII and International Council for Harmonization (ICH) Guideline E2C. All CTs were conducted in compliance with the Declaration of Helsinki, ICH Guidelines for Good Clinical Practice, and local country regulations. The protocols for the clinical trials were reviewed and approved by ethical review committees and authorities for each clinical site; all patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}